Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 6 recruiting now early-phase tilt small index

Neuro-Degenerative Disease: early-phase trial registry

6 of 12 indexed Neuro-Degenerative Disease trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,429 of 28,707 conditions by registered trial count.

12 US clinical trials · 6 currently recruiting · #1,429 of 28,707 conditions by registered trial count

Neuro-Degenerative Disease: 12 US clinical trials tracked, 6 recruiting.

Neuro-Degenerative Disease is the subject of 12 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Drexel University College of Medicine, running 2 of these trials.

Enrollment posture brief

Registry condition neuro-degenerative-disease

OPEN 6 | RECR 50% | LATE 0 | EARLY 2 | RANK #1429 | SPON 2

Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)

Neuro-Degenerative Disea (th…50%Acute Myeloid Leukemia in Re41.7%Adenocarcinoma of the Rectum41.7%Adherence, Patient16.7%Accelerated Phase Chronic My0%
Open-enrollment share among volume-matched conditions near Neuro-Degenerative Disease

Neuro-Degenerative Disease lists 6 open slots (50% of 12 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Neuro-Degenerative Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Neuro-Degenerative Disease is recruiting above its size-band peers.

    6 of 12 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Neuro-Degenerative Disease research.

    Drexel University College of Medicine accounts for 2 of 12 trials (16.7%). 11 distinct sponsors appear on at least one study for this condition label.

  3. Typical Neuro-Degenerative Disease enrolment sits around 90 participants.

    Median target enrolment is 90 among the 12 trials that report a genuine target (sentinel values excluded). 7 of those (58.3%) plan for fewer than 100 participants.

  4. Neuro-Degenerative Disease splits between interventional and observational designs.

    5 interventional and 7 observational studies make up this index (41.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 22

Open and recent trials

12 total, page 1 of 1

RECRUITING 5,000 participants

The Neurodevelopmental and Behavioral Phenotyping Screening Protocol

National Institute of Mental Health (NIMH)

NCT00271622

RECRUITING 360 participants

Persons With Dementia and Their Extended Family Caregivers

Karen Roberto

NCT04863859

RECRUITING Phase 2 300 participants

PET Tau - Neurodegenerative Disease Imaging

University of Pennsylvania

NCT03143374

RECRUITING Phase 2 90 participants

Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders

Carl Allen

NCT04079179

RECRUITING NA 90 participants

Mindfulness Walking Intervention to Enhance Resilience (iWalk)

University of Illinois at Urbana-Champaign

NCT07285954

RECRUITING 20 participants

A Prospective Natural History and Outcome Measure Discovery Study of Charcot-Marie-Tooth Disease, Type 4J

Elpida Therapeutics SPC

NCT06151600

ACTIVE NOT RECRUITING 2,000 participants

FA Clinical Outcome Measures

Friedreich's Ataxia Research Alliance

NCT03090789

COMPLETED NA 209 participants

A Culturally-Based Palliative Care Tele-consult Program for Rural Southern Elders

University of Alabama at Birmingham

NCT03767517

COMPLETED NA 35 participants

Golf Instruction Versus Tai Chi for People With Parkinson's Disease

Massachusetts General Hospital

NCT03563807

COMPLETED 25 participants

Comparing The Cyberlink Control System to the Manual Letter Board for Communication Purposes in the ALS Patient Population

Drexel University College of Medicine

NCT00718497

COMPLETED 20 participants

Cause and Pathogenesis of Neurometabolic Disorders

National Institute of Neurological Disorders and Stroke (NINDS)

NCT00016562

COMPLETED 11 participants

Cerebrospinal Fluid Repository

Drexel University College of Medicine

NCT00714636

Phase Distribution

PhaseTrial count
Phase 2 2

Named interventions

Most-linked intervention names on Neuro-Degenerative Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Active Intervention Other
1 trials
Tai Chi Class Other
1 trials
Golf Instruction Other
1 trials
18F-AV-1451 Drug
1 trials
iWalk Program Behavioral
1 trials
Cobimetinib Drug
1 trials
Usual Care Other
1 trials

US sites by state

Facility locations filed on Neuro-Degenerative Disease trials. A trial with sites in several states counts in each.

Pennsylvania 4 trials
Maryland 3 trials
California 3 trials
Texas 2 trials
Tennessee 2 trials
Massachusetts 2 trials
Iowa 2 trials
Wisconsin 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Neuro-Degenerative Disease page

12 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Neuro-Degenerative Disease condition card totals 12 registered trials; most-linked intervention Active Intervention; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.